BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 14, 2015
 |  BioCentury  |  Emerging Company Profile

Subcutaneous solution

Arsia is reducing biologics viscosity to enable subcutaneous delivery

Subcutaneous delivery of biologics can eliminate or reduce visits to a hospital or doctor's office, but at the high concentrations required, an increase in interactions between the molecules causes most biologics to become too viscous and painful to administer subcutaneously. Arsia Therapeutics Inc. is developing a library of excipients that disrupt the interactions between the protein molecules without interfering with the proteins themselves.

The company's technology consists of the excipients themselves, plus an algorithm that matches a particular biologic to an initial slate of excipients predicted to be optimally compatible based on undisclosed characteristics of the excipients and the therapeutics.

The library includes novel compounds discovered by co-founders Alex Klibanov and Robert Langer, both professors at the Massachusetts Institute of Technology.

It also includes excipients that have been used in other FDA-approved products or are GRAS...

Read the full 690 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >